Literature DB >> 33091175

Role of B Cells in Multiple Sclerosis and Related Disorders.

Giancarlo Comi1, Amit Bar-Or2, Hans Lassmann3, Antonio Uccelli4, Hans-Peter Hartung5, Xavier Montalban6, Per Solberg Sørensen7, Reinhard Hohlfeld8, Stephen L Hauser9.   

Abstract

The success of clinical trials of selective B-cell depletion in patients with relapsing multiple sclerosis (MS) and primary progressive MS has led to a conceptual shift in the understanding of MS pathogenesis, away from the classical model in which T cells were the sole central actors and toward a more complex paradigm with B cells having an essential role in both the inflammatory and neurodegenerative components of the disease process. The role of B cells in MS was selected as the topic of the 27th Annual Meeting of the European Charcot Foundation. Results of the meeting are presented in this concise review, which recaps current concepts underlying the biology and therapeutic rationale behind B-cell-directed therapeutics in MS, and proposes strategies to optimize the use of existing anti-B-cell treatments and provide future directions for research in this area. ANN NEUROL 2021;89:13-23.
© 2020 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33091175      PMCID: PMC8007167          DOI: 10.1002/ana.25927

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  101 in total

1.  Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.

Authors:  Diane Larsson; Torbjörn Åkerfeldt; Kristina Carlson; Joachim Burman
Journal:  Mult Scler       Date:  2019-07-26       Impact factor: 6.312

2.  Clinical presentation and prognosis in MOG-antibody disease: a UK study.

Authors:  Maciej Jurynczyk; Silvia Messina; Mark R Woodhall; Naheed Raza; Rosie Everett; Adriana Roca-Fernandez; George Tackley; Shahd Hamid; Angela Sheard; Gavin Reynolds; Saleel Chandratre; Cheryl Hemingway; Anu Jacob; Angela Vincent; M Isabel Leite; Patrick Waters; Jacqueline Palace
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

3.  Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.

Authors:  Natalia B Pikor; Jillian L Astarita; Leslie Summers-Deluca; Georgina Galicia; Joy Qu; Lesley A Ward; Susan Armstrong; Claudia X Dominguez; Deepali Malhotra; Brendan Heiden; Robert Kay; Valera Castanov; Hanane Touil; Louis Boon; Paul O'Connor; Amit Bar-Or; Alexandre Prat; Valeria Ramaglia; Samuel Ludwin; Shannon J Turley; Jennifer L Gommerman
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

4.  Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers.

Authors:  Laure Michel; Camille Grasmuck; Marc Charabati; Marc-André Lécuyer; Stephanie Zandee; Tessa Dhaeze; Jorge I Alvarez; Rui Li; Sandra Larouche; Lyne Bourbonnière; Robert Moumdjian; Alain Bouthillier; Boaz Lahav; Pierre Duquette; Amit Bar-Or; Jennifer L Gommerman; Evelyn Peelen; Alexandre Prat
Journal:  Sci Transl Med       Date:  2019-11-13       Impact factor: 17.956

5.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

6.  Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.

Authors:  Arumugam Palanichamy; Leonard Apeltsin; Tracy C Kuo; Marina Sirota; Shengzhi Wang; Steven J Pitts; Purnima D Sundar; Dilduz Telman; Lora Z Zhao; Mia Derstine; Aya Abounasr; Stephen L Hauser; H-Christian von Büdingen
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

Review 7.  Targets of the humoral autoimmune response in multiple sclerosis.

Authors:  Judith Fraussen; Nele Claes; Laura de Bock; Veerle Somers
Journal:  Autoimmun Rev       Date:  2014-08-06       Impact factor: 9.754

8.  A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.

Authors:  X Montalban; J Sastre-Garriga; M Tintoré; L Brieva; F X Aymerich; J Río; J Porcel; C Borràs; C Nos; A Rovira
Journal:  Mult Scler       Date:  2009-09-29       Impact factor: 6.312

9.  Lack of association between antimyelin antibodies and progression to multiple sclerosis.

Authors:  Jens Kuhle; Christoph Pohl; Matthias Mehling; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Chris H Polman; David H Miller; Xavier Montalban; Frederik Barkhof; Lars Bauer; Susanne Dahms; Raija Lindberg; Ludwig Kappos; Rupert Sandbrink
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

10.  The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.

Authors:  Joana Machado-Santos; Etsuji Saji; Anna R Tröscher; Manuela Paunovic; Roland Liblau; Galina Gabriely; Christian G Bien; Jan Bauer; Hans Lassmann
Journal:  Brain       Date:  2018-07-01       Impact factor: 15.255

View more
  32 in total

Review 1.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 2.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 3.  A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.

Authors:  Jeri Burtchell; Daisy Clemmons; Joann Clemmons; Tim Sabutis; Adeline Rosenberg; Jennifer Graves; Michael L Sweeney; John Kramer; Marina Ziehn; Brandon Brown; Jamie L Weiss; Ahmed Z Obeidat
Journal:  Neurol Ther       Date:  2022-05-24

4.  Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.

Authors:  Guillaume Dorcet; Hugo Migné; Damien Biotti; Chloé Bost; Fleur Lerebours; Jonathan Ciron; Emmanuel Treiner
Journal:  J Neurol       Date:  2022-06-02       Impact factor: 6.682

5.  Integration of Genetic and Immune Infiltration Insights into Data Mining of Multiple Sclerosis Pathogenesis.

Authors:  Xiaoyun Zhang; Ying Song; Xiao Chen; Xiaojia Zhuang; Zhiqiang Wei; Li Yi
Journal:  Comput Intell Neurosci       Date:  2022-06-27

Review 6.  Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.

Authors:  Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 7.  Therapeutic Advances in Multiple Sclerosis.

Authors:  Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves
Journal:  Front Neurol       Date:  2022-06-03       Impact factor: 4.086

Review 8.  Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications.

Authors:  Manon Galoppin; Saniya Kari; Sasha Soldati; Arindam Pal; Manon Rival; Britta Engelhardt; Anne Astier; Eric Thouvenot
Journal:  Brain Commun       Date:  2022-06-30

Review 9.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

Authors:  Vyanka Redenbaugh; Eoin P Flanagan
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

10.  Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis.

Authors:  Molly E Church; Guadalupe Ceja; Megan McGeehan; Miles C Miller; Priscilla Farias; Melissa D Sánchez; Gary P Swain; Charles-Antoine Assenmacher; Edward G Stopa; Charles H Vite; Amit Bar-Or; Jorge I Alvarez
Journal:  J Immunol       Date:  2021-06-23       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.